HIK Share Price Performance
UK£12.45
-8.35 (-40.14%)
34.7% undervalued intrinsic discount
UK£19.06
Fair Value
Price UK£12.45
AnalystConsensusTarget UK£19.06
AnalystLowTarget UK£13.61
AnalystHighTarget UK£26.36
Fair ValueUK£19.06
Share Pricen/a
Hikma Pharmaceuticals PLC Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 56 Fair Values set on narratives written by author
HIK Community Narratives
AN
Fair Value UK£19.06 34.7% undervalued intrinsic discount
Expanded US Market Access Will Drive Momentum Amid Regulatory Headwinds
1users have liked this narrative
0users have commented on this narrative
32users have followed this narrative
AN
Fair Value UK£13.61 8.5% undervalued intrinsic discount
Injectable Expansion And MENA Scale Will Shape A Cautious Yet Steady Outlook
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value UK£26.36 52.8% undervalued intrinsic discount
Rising CMO And Injectable Pipelines Will Support A Stronger Long Term Outlook
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Expanded US Market Access Will Drive Momentum Amid Regulatory Headwinds
Key Takeaways Expanding global manufacturing and focus on complex generics position Hikma to benefit from rising pharmaceutical demand and the shift toward more cost-effective health solutions. Robust R&D, resilient MENA operations, and strong supply chain compliance provide higher-margin growth, stable performance amid regional volatility, and greater reliability than import-dependent peers.Read more
329
users have viewed this narrative1users have liked this narrative
0users have commented on this narrative
32users have followed this narrative
AN
UK£19.06
34.7% undervalued intrinsic discount
Fair Value
Revenue
4.42% p.a.
Profit Margin
12.78%
Future PE
13.94x
Price in 2029
UK£23.39
Injectable Expansion And MENA Scale Will Shape A Cautious Yet Steady Outlook
Catalysts About Hikma Pharmaceuticals Hikma Pharmaceuticals develops and supplies generic and branded medicines, including injectables, across MENA and the US. What are the underlying business or industry changes driving this perspective?Read more
5
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
UK£13.61
8.5% undervalued intrinsic discount
Fair Value
Revenue
3.86% p.a.
Profit Margin
10.69%
Future PE
12.1x
Price in 2029
UK£16.77
Rising CMO And Injectable Pipelines Will Support A Stronger Long Term Outlook
Catalysts About Hikma Pharmaceuticals Hikma Pharmaceuticals develops, manufactures, and supplies branded, generic, and injectable medicines across MENA, Europe, and North America. What are the underlying business or industry changes driving this perspective?Read more
44
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
UK£26.36
52.8% undervalued intrinsic discount
Fair Value
Revenue
5.97% p.a.
Profit Margin
16.15%
Future PE
14.85x
Price in 2029
UK£32.47
Trending Discussion
Recently Updated Narratives
AN
HIK: Buyback Plan And Leadership Changes Will Support Future Re Rating
Fair Value: UK£19.06 34.7% undervalued intrinsic discount
32 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Injectable Expansion And MENA Scale Will Shape A Cautious Yet Steady Outlook
Fair Value: UK£13.61 8.5% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Rising CMO And Injectable Pipelines Will Support A Stronger Long Term Outlook
Fair Value: UK£26.36 52.8% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Hikma Pharmaceuticals PLC Key Details
About HIK
- Founded
- 1978
- Employees
- 9400
- CEO
- WebsiteView website
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, specialty, and branded pharmaceutical products. The company operates through three segments: Injectables, Hikma Rx, and Branded. The Injectables segment provides generic and specialty injectable products primarily for use in hospitals. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The Hikma Rx segment offers oral, respiratory, and other generic and specialty products for the retail market. It provides its products in various therapeutic areas, including respiratory, oncology, and pain management. The company also offers its products in solid, semi-solid, liquid, and injectable dosage forms. It operates in the United Kingdom, Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, United Kingdom.
